drugset / Trial / NCT07560475

Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients

NCT07560475

Phase 2 Not yet recruiting 60 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

An Exploratory Study on the Efficacy and Safety of Different Administration Routes of SHR-A1811 in the Treatment of HER2-Positive Advanced Breast Cancer

Timeline

Start
2026-06-10
Primary completion
2028-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Rezetecan Monoclonal antibody